Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RPC 4046

Drug Profile

RPC 4046

Alternative Names: ABT-308; RPC-4046

Latest Information Update: 13 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie; Receptos
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Eosinophilic oesophagitis
  • Discontinued Allergic asthma

Most Recent Events

  • 24 Oct 2018 RPC 4046 is still in phase II trials for Eosinophilic esophagitis (Celgene pipeline, October 2018)
  • 20 Oct 2018 Pharmacodynamic data from a phase II trial in Eosinophilic oesophagitis presented at the 26th United European Gastroenterology Week (UEGW-2018)
  • 20 Oct 2018 Safety and efficacy data from the phase II HEROES trial and an open-label extension trial in Eosinophilic oesophagitis presented at the 26th United European Gastroenterology Week (UEGW-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top